KalVista Pharmaceuticals, Inc. announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual… read more.
KalVista Pharmaceuticals, Inc. announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025. Details are as follows: Thursday,… read more.
The European Regulation list on mandatory labelling of foods includes 14 allergenic foods. Research published in Clinical & Experimental Allergy has identified eight additional foods frequently involved in food-induced anaphylaxis…. read more.
For some, the word “histamine” might evoke thoughts of seasonal allergies: runny noses, scratchy throats and itchy eyes. But the molecule also influences exercise performance. A new study… read more.
KalVistA Pharmaceuticals Inc. announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom… read more.
Connect Biopharma Holdings Limited (a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations… read more.
New research published in Allergy indicates that certain environmental exposures may affect a child’s risk of developing atopic eczema, a condition characterized by dry, itchy, and inflamed skin. In other… read more.
ALK-Abello announced that its European regulatory filing for Itulazax (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been… read more.
The first clinical trial to test whether adults allergic to peanuts can be desensitised has shown great success with two thirds of the cohort consuming the equivalent of… read more.
The FDA approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who… read more.
29th EAHP Congress highlights Approximately 10% of inpatients are labelled as ‘allergic to penicillin’ but the vast majority have not experienced a true allergic reaction. Having a penicillin… read more.
Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further evidence supporting the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
